Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pheast Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Danish Gynecological Cancer Group
National Cancer Institute (NCI)
AstraZeneca
AstraZeneca
Fate Therapeutics
Merck Sharp & Dohme LLC
BioNTech SE
Eisai Inc.
Eisai Inc.
M.D. Anderson Cancer Center
GlaxoSmithKline
AstraZeneca
Ohio State University Comprehensive Cancer Center
University of Oklahoma
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC